High Court Snubs Teva Bid To Stay Copaxone Invalidity Ruling

Law360, New York (November 14, 2013, 1:17 PM EST) -- The U.S. Supreme Court's chief justice on Wednesday denied Teva Pharmaceuticals USA Inc.'s request to stay a lower court's invalidation of patents for Teva’s lucrative multiple sclerosis drug Copaxone, enabling Mylan Inc. and Sandoz Inc. to launch competing generics next spring rather than in 2015.

The high court announced, without elaborating, that Chief Justice John Roberts had rejected Teva's petition to put on hold the Federal Circuit’s ruling that five of the nine patents covering Copaxone were invalid while Teva appealed.

Teva had told the Supreme...
To view the full article, register now.